Summary Decarbazine is an imidazole dimethyltriazene with reproducible activity in patients with metastatic melanoma. CBIO-277 is a phenyl dimethyltriazene which, like dacarbazine, requires metabolic activation to its corresponding monomethyl species for antitumour activity. In preclinical models (human melanoma xenografts and transplantable rodent tumours) CB10-277 showed a similar spectrum and level of activity when compared to dacarbazine. Pharmacokinetic studies were performed with CBIO-277 in mice treated i.v. at the LDIO (750 mg m-2) and plasma analysed by HPLC. The parent drug area under the plasma concentration vs time curve (AUC) was 142 mM x minutes). Drug metabolism occurred as evidenced by the HPLC identification of the monomethyl species (AUC = 8 mM x minutes) as well as other metabolites.
The antitumour activity of triazenes was first observed in animal tumours at the Southern Research Institute during development of inhibitors of nucleic acid synthesis (Shealy et al., 1962) . The basic triazene structure is shown in Figure 1 . Compounds with different R, substitutents in position at N' (Loo & Lin, 1972; Audette et al., 1973; Connors et al., 1976; Loo et al., 1976; Giraldi et al., 1977; Hatheway et al., 1978; Wilman & Coddard, 1980; Gescher et al., 1981) and R2 and R3 substituents at N3 (Audette et al., 1973; Connors et al., 1976; Hatheway et al., 1978; Wilman & Goddard, 1980; Gescher et al., 1981; Shealy & Krauth, 1966; Vaughn et al., 1984) have been studied by various groups for activity in animal tumours. While a range of structural variations at RI can be tolerated, it is generally accepted that at least one methyl group is required at either R2 or R3 in order to allow the formation of a monomethyl species for antitumour activity (Audette et al., 1973) .
Dimethyltriazenoimidazolecarboxamide (dacarbazine, Figure  2a ) has reproducible antitumour activity in patients with lymphoma, sarcomas, and melanomas (Beretta et al., 1976) and is frequently used in the treatment of patients with recurrent melanoma because there are few chemotherapeutic alternatives. Dacarbazine undergoes in vitro decomposition in aqueous solution at physiologic pH (Shealy & Krauth, 1966) . These decomposition products are not thought to contribute to in vivo antitumour activity (Julliard & Vernin, 1981) . However, in vivo metabolite activation of dacarbazine by N-demethylation (as shown in Figure 2 ) is thought to be required for antitumour activity (Bono, 1976) . The hydroxymethyl ( Figure 2b ) and the monomethyl (Figure 2c ) intermediates formed during in vivo activation are chemically unstable and heat labile. Either the monomethyl species, or the methyl carbonium ion formed from it, is capable of methylating DNA (Julliard & Vernin, 1981) . However, methylation of DNA is not the sole determinant of cytotoxicity. In a cell line deficient in repairing DNA alkylations at the 06 position of guanine (Mer-) the hydroxymethyl and the monomethyl species ( Figure 2B , C respectively) showed greater antitumour activity than the parent compound (Gibson et al., 1986) . In contrast, in a cell line capable of 06 guanine alkylation repair (Mer+) the three compounds were equitoxic.
1-(4-carboxyphenyl)-3,3-dimethyltriazene (CBIO-277, Figure  2a ) is a dacarbazine analog which is soluble and stable in aqueous solution at physiologic pH (Wilman & Goddard, 1980) . CBIO-277 required metabolic activation, similar to that of dacarbazine (Figure 2 ), for antitumour activity (Connors et al., 1976; Julliard & Vernin, 1981; Bono, 1976) . In rats CB1O-277 was activated more readily than dacarbazine (Rutty et al., 1986 LD50 were 265 mg kg-' (800 mg m-2) and 343 mg kg-' (1030 mg M-2), respectively. The dose limiting toxicity was myelosuppression (BIBRA, 1988) . Other findings were weight loss, mottled liver (with elevated transaminases at high doses), conjunctivitis, piloerection and alopecia. In the present study, we compared dacarbazine and CB1O-277 in preclinical tumour models before starting the Phase I trial of CBIO-277. CBIO-277 pharmacokinetics were studied in mice and patients for interspecies comparisons of parent drug clearance and metabolism. This is a report of our preclinical studies and Phase I trial with pharmacokinetics of CBIO-277 given by intermittent short infusion. (Selby et al., 1980 (Morrison, 1983) . Group mean values were obtained and the relative values for treated (T) and control (C) groups expressed as a percentage (T/C).
Materials and methods

Drugs
Rodent tumours The rodent tumour models described in Table I were used (Audette et al., 1973; Potter & Robertson, 1960; Rosenoer et al., 1966 Weekly follow-up with physical examination, blood or serum studies to evaluate for possible bone marrow, renal and hepatic toxicity were performed. Repeat of previously positive radiological studies were performed every 6-9 weeks or sooner when indicated. Response and toxicity were graded by standard WHO criteria (WHO, 1979) .
Phase I treatment The starting dose was 80 mg m2 (1/10 the mouse LDIO). CB1O-277 was reconstituted in normal saline to give a 50 mg ml-' solution. Therefore, as the dose was escalated the solution volume increased. At the dose of 2,000 mg m-2 and above the infusion time became >O min with the longest infusion time being 35 min. Treatment was repeated every 21 days. Eleven escalations were used to reach the maximum tolerated dose (MTD) 6,000 mg m-2. A geometric dose escalation scheme was used to 600 mg m-2 when it became obvious that the toxic effects per unit dose in patients were less than those in mice. Thereafter, escalations of 30-50% over the previous level were used until WHO grade 3 toxicity that precluded further escalation was observed in 2/3 of patients treated with the same dose. Intrapatient escalations were allowed. Patients received two or more courses unless obvious progressive disease was present after the first course.
Pharmacokinetics
Plasma samples were obtained from heparinised blood kept at 0°C and taken at 5, 10, 15, 30, 60, 120, 240, 480, 720 and 1080 min after completion of the short infusion. Plasma samples were prepared for HPLC analysis as described above for mouse plasma. Table II . The whole mouse body weight differences in the drug treated groups (start of treatment -end of the treatment) did not differ from the nontreated control by >10%. The activity levels of CBIO-277 and dacarbazine showed variations between models, e.g. Hx 47 and PXN/24 human melanoma xenografts tumour volume % T/C was 3 and 8 vs 135 and 71 respectively; ADJ/PC6 plasmacytoma and Walker 256 ED 90 of 2-11 vs 52-64 mg kg-', respectively. However, the activity levels of the two compounds were similar within each rodent model, e.g. against TLX/5 CBIO-277 produced % ILS of 72 ± 11 with the optimal dose range being 25-100 mg kg-I while dacarbazine produced % ILS of 81 ± 17 with the optimal dose range being 12.5-50 mg kg-'. Although the CBIO-277 result in the L1210 model (% ILS 37, optimal dose 100 mg kg-') was double the result observed with dacarbazine (% ILS 18, same optimal dose) these were from one experiment and represents activity of little significance in either case.
Pharmacokinetics The plasma levels of CBIO-277 and its monomethyl metabolite in mice are shown in Figure 3 . All mouse plasma samples had detectable levels of CBIO-277 up to and including 120 min. At 240 min three out of four samples had detectable levels, but the time points after 240 min had levels inconsistently detected. The latter time points were not included in the pharmacokinetic analysis due which became evident after starting CB10-277. Patient 'I' had a complete response 2 months after starting treatment and has remained in remission for 6 months off CB10-277. The patient 'P' with sarcoma had exploratory surgery 6 months after starting treatment. The pelvic mass had clinically resolved and was not surgically detectable, but the pulmonary lesions had increased in size and were histologically diagnosed as sarcoma. Response durations have been 6 months or less except for patient 'I'. Pharmacokinetics Pharmacokinetics were performed in 46 courses. The AUC of CB10-277 increased with dose as shown in Figure 4 (linear regression correlation coefficient = 0.9203, P<0.0001). The monomethyl species was detected in plasma of some patients treated with g 900 mg m-2. Two of the seven patients treated at the MTD (6,000 mg m-2) were studied and their peak monomethyl metabolite plasma levels were 18 and 32 M. These levels were the highest detected in all the patients. The monomethyl metabolite AUC was 1.8 mM x minutes for the first patient and 3.7 mM x minutes for the second patient. Again, these represented the highest values observed. The plasma levels of CB10-277 and its monomethyl metabolite in these two patients treated with 6,000 mg m2 are shown in Figure 5 .
Discussion
The need for improved treatment in patients with dacarbazine sensitive tumours, particularly malignant melanoma is generally accepted (Mastrangelo et al., 1985) . Even adjuvant treatment of patients with stage I melanoma has been disappointing with currently available drugs and showed no improvement in survial for the treated vs nontreated controls (Veronesi et al., 1982; Tranum et al., 1987) . Never the less, dacarbazine has reproducible antitumour activity in patients with cutaneous melanoma and for an individual patient the 0) treated at the maximum tolerated dose (6000 mg mi2). response (complete or partial) can be meaningful with durations sometimes greater than 12 months (Comis, 1976) .
Dacarbazine is an imidazole dimethyltriazene that is poorly soluble and unstable in aqueous solution at physiologic pH. It requires metabolic activation with formation of a monomethyl triazene for anti-tumour activity (Audette et al., 1973; Gescher et al., 1981) . Although the ability to form a monomethyl species is required for antitumour activity, this may not be the sole mechanism by which triazenes exert their in vivo antitumour activity (Gescher et al., 1981; Sava et al., 1988) . Some Mer-cells are relatively sensitive to the monomethyl species of dacarbazine in vitro, but it is unclear whether this phenotype is a direct or indirect determinant of the lethal effects of triazenes (Gibson et al., 1986; Lunn & Harris, 1988) . However, even if monomethyl metabolite formation is not the sole determinant of activity, a higher level might be expected to be associated with improved activity.
Numerous compounds with structural similarities to dacarbazine that have preclinical activity exist (Loo & Lin, 1972; Audette et al., 1973; Connors et al., 1976; Loo et al., 1976; Giraldi et al., 1977; Hatheway et al., 1978; Wilman & Goddard, 1980; Gescher et al., 1981; Shealy & Krauth, 1966; Vaughn et al., 1984) . CB10-277, a phenyl dimethyltriazene, is soluble and stable in aqueous solutions at physiologic pH (Wilman & Goddard, 1980) . The level of formation of the monomethyl species from CB10-277 and from dacarbazine was similar in mice, but the levels of the monomethyl formed from CB10-277 was higher in rats when compared to those formed from dacarbazine (Rutty et al., 1986 ). In our preclinical models, CB10-277 demonstrated comparable antitumour activity to dacarbazine on a multiple dose schedule. Similar results in other models have been reported by other investigators, who also noted no significant difference in haematologic toxicity (Colombo & D'Incalci, 1984 Therefore, although qualitative species similarities in CB10-277 metabolism in mice and patients were detected, clear quantitative differences exist. Not only do patients have a higher plasma clearance of the parent compound, they are less efficient in forming the monomethyl metabolite. Despite the monomethyl levels in patients being less than expected, based on the predictions from mice studies, they were more than double levels that have been shown to produce in vitro cytotoxicity with similar monomethyl triazenes (Gibson et al., 1986; Gibson et al., 1986a) .
As with dacarbazine, nausea and vomiting were dose limiting. Except for the flushing sensation, which was short lived and self limiting, other toxicities were infrequent. Of particular interest was that no evidence of myelosuppression or liver function abnormalities were observed with administration of CB10-277 by short infusion. There were one complete and two partial responses in patients with metastatic melanoma. One patient with recurrent carcinoid also had a partial response. Additional evidence of antitumour activity (mixed responses, tumour necrosis at autopsy) occurred in patients with melanoma and sarcoma. Athough the responses occurred in patients who arguably might have responded to dacarbazine and occurred in subcutaneous, nodal or lung disease; the patients were not required to remain in the hospital for treatment nor return daily for 5 days. In addition, the nausea and vomiting, even in patients with the most severe symptoms, resolved by 24 h.
An additional Phase I study of CB10-277 using a 24 h continuous infusion was performed to investigate whether the severity of the acute nausea and vomiting could be reduced. Details of the 24 h continuous infusion study and further discussion of the rationale are given in the accompanying manuscript. The usefulness of CB10-277 in dacarbazine sensitive histologies can best be determined by a randomised comparison of the two drugs. The dose and schedule of CB10-277 recommended for future studies is given and discussed in the 24 h continuous infusion manuscript. 
